Marwan Sabbagh, MD

Treatment does not end with a prescription. The panel closes by examining who owns follow-up care, and why caregivers remain the true cornerstone of managing Alzheimer's agitation over time.

When first-line therapy falls short, the decision to augment or switch is rarely straightforward. The panel examines that decision-making process alongside neurology's evolving role in managing agitation.

Specialty care approaches shared decision-making differently, and the stakes extend beyond a single symptom. The panel closes this discussion by debating whether treating agitation can shift disease trajectory itself.

With two on-label options now available, the choice between them comes down to comorbidities, psychosis, and risk. The panel also examines how long-term care rating pressures complicate that decision in practice.

Longer follow-up and real-world claims data add context that pivotal trials alone cannot provide. The panel examines both, alongside how monitoring for response actually happens in daily practice.

A second on-label option carries its own distinct mechanism and its own trial history. The panel details how this antipsychotic therapy was studied and what its data actually show.

Safety data, not just efficacy, determines how comfortable clinicians feel prescribing. The panel reviews the safety profile, dosing schedule, and drug interactions relevant to a newer agitation therapy.

Pivotal trial data can reshape when clinicians feel comfortable starting treatment. The panel walks through the short- and long-term study results behind a newer agitation therapy in detail.

Two on-label options are not enough for every patient. The panel weighs the field's remaining unmet needs against the biological rationale behind a newer, non-antipsychotic approach to treatment.

Decades of off-label prescribing for agitation associated with dementia due to Alzheimer’s are colliding with new evidence and new regulation. The panel examines why practice has lagged behind the data, and what is now changing.

Before any prescription is written, non-pharmacologic strategies and a structured framework guide the panel's approach to agitation, alongside a biological explanation for why redirection so often fails.

Agitation does not stay contained to the patient. The panel examines the data linking agitation to caregiver burden, and the communication gaps that complicate coordinating care across specialties.

Agitation eventually affects nearly every patient with Alzheimer's disease, yet it rarely looks like simple aggression. The panel outlines how common it is, the many forms it takes, and why it so often goes unrecognized.

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel walks through the clinical differences and where formal screening scales genuinely fit into daily practice.

Sharon Cohen, MD, and Marwan Sabbagh, MD, share their final thoughts on Alzheimer's disease and offer advice on strategies to reduce the risk of developing AD and slow the progression of the disease for those already affected.

Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.

Medical experts discuss the application of ApoE gene polymorphism and copy number data in managing Alzheimer's disease, highlighting its relevance for individuals with a family history of AD, and symptomatic patients.

Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.

Key opinion leaders emphasize the significance of early diagnosis in Alzheimer's disease, as it allows patients to make autonomous decisions and access early treatment options, including potential participation in clinical trials.

Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.

In this episode of MEDcast, expert geriatric psychiatrist and neurologist delve into the recent advances in the treatment of Alzheimer’s disease. We will discuss treatments that are on the cusp of FDA approval and others that are coming down the pipeline.

In this episode of MEDcast, expert geriatric psychiatrist and neurologist delve into the recent advances in the treatment of Alzheimer’s disease. We will discuss treatments that are on the cusp of FDA approval and others that are coming down the pipeline.

Drs Atri, Cohen, Sabbagh and McDade share their enthusiasm and optimism about the future outlook for Alzheimer’s disease.

Dr Eric McDade shares information on different types of prevention trials to manage Alzheimer’s disease.

Expert neurologists share information on drugs with different mechanisms of actions that are being evaluated in clinical trials for Alzheimer’s disease.

Drs McDade and Atri discuss differences and similarities between other ongoing anti-amyloid antibody trials in Alzheimer’s disease.

Drs Cohen, Atri, and Sabbagh share data on lecanemab, an anti-amyloid beta antibody, that was presented at CTAD 2022.

Dr Atri comments on observation of amyloid related imaging abnormalities (ARIA) seen with many Alzheimer’s disease treatments and shares his thoughts on management of ARIA.

Dr Atri discusses aducanumab, first FDA approved anti-amyloid-beta antibody for treatment of Alzheimer’s disease.

Drs McDade, Atri, Cohen, and Sabbagh discuss candidates drugs and various mechanisms of actions that are currently under evaluation for Alzheimer’s disease.